The United States Food and Drug Administration has officially approved tavapadon, a next-generation dopamine-based therapy developed for the management of…
Read More
Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data
AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read MoreYOU MAY HAVE MISSED
